ArticleJournal of neuro-oncology2026
BOLD complexity characterizes glioblastoma survival via voxel-wise and localized sample entropy.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeGlioblastoma (GBM) is the most prevalent and lethal primary brain tumor. Non-invasive presurgical biomarkers are urgently needed to predict patients’ overall survival (OS). Here we demonstrated a nuanced prognostic tool using sample entropy to assess Blood-Oxygen-Level-Dependent (BOLD) complexity and predict survival outcome, which is computationally efficient, reproducible, robust to noise, and readily transferable across cohorts.
methodsResting-state fMRI from 205 treatment-naïve GBM patients and 1148 cognitively stable healthy controls were evaluated. Sample entropy (SampEn), a complexity metric, was evaluated in relation to OS at four levels: whole brain voxel-wise, 15 resting state networks (RSNs), a 64-feature autoencoded latent space, and complexity dynamics along contrast-enhancing (CE) boundary.
resultsGBM patients showed a significant reduction in global SampEn versus controls (p < 0.001). Among RSNs, medial temporal lobe (MTL) and basal ganglia (BGA) SampEn correlated inversely with OS (R² = 0.033 and 0.034; p = 0.008 and 0.006). The latent-space-dependent Cox risk score stratifies patients into high and low survival populations (p < 0.001). The number of SampEn peaks at the CE boundary also correlated negatively with OS (R² = 0.020, p = 0.037).
conclusionsVoxel-wise SampEn revealed widespread loss of BOLD complexity in GBM. It identifies influences at RSNs and tumor-edge, characterizing survival. Latent space analysis revealed whole-brain SampEn characteristics, which provide a compact, data-driven biomarker that augments conventional Cox modelling and stratifies the patient survival. These findings show fMRI-derived SampEn measures are efficient and robust for risk stratification and mechanistic insight in glioblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.